China Pharma Holdings, Inc. (CPHI): Shareholders' Equity
$22.74M
As of 2025-12-31
$36.18M
As of 2026-06-30
+74.4%
3-year compound annual growth
+23.2%
5-year compound annual growth
-11.0%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $22.74M | +193.5% | 2026-04-01, Balance as of period end |
| 2024-12-31 | $7.75M | +3.9% | 2026-04-01, Balance as of period end |
| 2023-12-31 | $7.45M | +73.8% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $4.29M | -28.7% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $6.02M | -24.8% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $8.00M | -13.3% | 2022-03-30, Balance as of period end |
| 2019-12-31 | $9.24M | -69.4% | 2021-03-26, Balance as of period end |
| 2018-12-31 | $30.20M | -29.9% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $43.07M | -26.9% | 2019-03-28, Balance as of period end |
| 2016-12-31 | $58.91M | -18.9% | 2018-04-02, Balance as of period end |
| 2015-12-31 | $72.64M | -21.7% | 2017-03-31, Balance as of period end |
| 2014-12-31 | $92.74M | -30.2% | 2016-03-30, Balance as of period end |
| 2013-12-31 | $132.94M | -10.5% | 2015-12-28, Balance as of period end |
| 2012-12-31 | $148.52M | +4.2% | 2014-03-20, Balance as of period end |
| 2011-12-31 | $142.48M | +20.8% | 2013-03-14, Balance as of period end |
| 2010-12-31 | $117.94M | n/a | 2012-03-14, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $22.74M | +193.5% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $18.22M | -53.5% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $3.51M | -52.3% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $16.80M | -9.5% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $47.70M | -24.5% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $3.21M | -13.3% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $7.40M | +23.1% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $339.77M | -27.7% |
Compare CPHI, CRVO, PRPH, MRKR side by side · Screen every company in Pharmaceutical Preparations ↗